Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Chicago
About this trial
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.
Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Eligibility criteria
Qualifiers
Subject must be ≥ 18 years of age.
Life expectancy of more than three months.
Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
Subject must have adequate organ function, defined by clinically confirmed lab values set by the study team.
Disqualifiers
Waldenström's macroglobulinemia, systemic amyloidosis, POEMS syndrome, or plasma cell leukemia at the time of screening.
Radiotherapy to multiple sites within 3 weeks before start of protocol treatment (localized radiotherapy to a single site 1 week before start is permissible).
Subject must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days preceding the first dose of study drug.
Prior refractory status to belantamab mafodotin. Concurrent Conditions
Trial design
Treatments tested in this trial
- Belantamab mafodotin
- Carfilzomib
- Pomalidomide
- Dexamethasone
Treatment groups
83 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov